Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Fast Is The Clinical Oncology Next Generation Sequencing Market Expected to Grow Between 2025 And 2029?

Recent years have seen the rapid expansion of the clinical oncology next generation sequencing market. Projected growth rates indicate an increase from $0.51 billion in 2024 to $0.58 billion in 2025, marking a compound annual growth rate (CAGR) of 14.8%. This impressive growth throughout the historical period can be traced back to advancements in genomic research, the discovery of cancer biomarkers, technological progression, and regulatory approvals.

What Growth Rate Is Anticipated for the Clinical Oncology Next Generation Sequencing Market in the Coming Years?

In the forthcoming years, the market size of next generation sequencing in clinical oncology is projected to surge swiftly. The estimation predicts a rise to $0.95 billion by 2029, reflecting a compound annual growth rate (CAGR) of 12.9%. Factors contributing to this trend in the forecast period are escalating cases of cancer, accuracy in medicine, immuno-oncology, and liquid biopsies. The predominant trends that are expected to be observed in the forecast period include comprehensive genomic profiling (cgp), developments in immuno-oncology, evolution and heterogeneity of tumors, and the use of artificial intelligence and machine learning.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

Who Are the Leading Companies in the Clinical Oncology Next Generation Sequencing Market?

Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

What Are the Key Drivers of the Clinical Oncology Next Generation Sequencing Market?

The increasing prevalence of cancer worldwide is projected to drive the expansion of the clinical oncology next-generation sequencing market in the coming years. The National Cancer Institute, a government agency in the US, reported approximately 18.1 million cancer survivors in the country as of May 2024. This number is expected to climb to 22.5 million by the year 2032. Further estimates suggest that by 2040, the annual tally of novel cancer cases would touch 29.9 million, and there would be an estimated 15.3 million cancer-related deaths. Hence, the global surge in cancer occurrences is poised to stimulate the need for and augment the growth of the clinical oncology next-generation sequencing market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=3344&type=smp

What Are the Key Market Segments in the Clinical Oncology Next Generation Sequencing Industry?

The clinical oncology next generation sequencing market covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing

2) By Application: Screening, Companion Diagnostics, Other Diagnostics

3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic Laboratories

Subsegments:

1) By Ion Semiconductor Sequencing: Ion Proton System, Ion PGM System, Ion S5 System, Other Ion Semiconductor Sequencing Technologies

2) By Pyro-Sequencing: 454 Pyrosequencing, Other Pyro-Sequencing Technologies

3) By Synthesis Sequencing: Illumina Sequencing Technology, SOLiD Sequencing Technology, Other Synthesis Sequencing Technologies

4) By Real-Time Sequencing: PacBio RS II System, Sequel System, Other Real-Time Sequencing Technologies

5) By Ligation Sequencing: Helicos Single Molecule Sequencing, Other Ligation Sequencing Technologies

6) By Reversible Dye Termination Sequencing: Illumina HiSeq, Illumina NextSeq, Other Reversible Dye Termination Sequencing Technologies

7) By Nano-Pore Sequencing: Oxford Nanopore Technologies (MinION, GridION, PromethION), Other Nano-Pore Sequencing Technologies

What Are the Latest Trends in the Clinical Oncology Next Generation Sequencing Market?

Leading firms in the clinical oncology next-generation sequencing sector are introducing innovative products like the BenchMark ULTRA PLUS system to boost their market earnings. Especially useful in cancer diagnostics and research, the BenchMark ULTRA PLUS System is a substantial resource for clinical labs as it bolsters the precision and effectiveness of diagnostic examinations, thus enhancing patient care. In June 2022, for example, Roche, a pharmaceutical organization based in Switzerland, unveiled its most advanced tissue staining platform, the BenchMark ULTRA PLUS system. This system provides quick and accurate test results, aiding healthcare professionals in making prompt therapy decisions for their patients.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

What Are the Key Regional Markets in the Clinical Oncology Next Generation Sequencing Industry?

North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=3344

This Report Delivers Insight On:

1. How big is the clinical oncology next generation sequencing market, and how is it changing globally?

2. Who are the major companies in the clinical oncology next generation sequencing market, and how are they performing?

3. What are the key opportunities and risks in the clinical oncology next generation sequencing market right now?

4. Which products or customer segments are growing the most in the clinical oncology next generation sequencing market?

5. What factors are helping or slowing down the growth of the clinical oncology next generation sequencing market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model